Advanced

Prognosis and clinical presentation of BRCA2-associated breast cancer

Loman, Niklas LU ; Johannsson, O; Bendahl, Pär-Ola LU ; Dahl, N; Einbeigi, Z; Gerdes, A; Borg, Åke LU and Olsson, Håkan LU (2000) In European Journal of Cancer 36(11). p.1365-1373
Abstract
54 female breast cancer patients from 22 families with BRCA2 germ line mutations from Sweden and Denmark were compared with 214 age- and date of diagnosis-matched controls identified among breast cancer patients from South Sweden. At diagnosis, BRCA2-associated cases were more often node-positive (N+). OR=1.9 (95% confidence interval (CI)=1.0-3.6; P=0.036), and were more often clinical stage IV: OR=4.6 (95% CI=1.3-17; P=0.021) than the controls. Bilateral disease was also more common among the BRCA2-associated cases: OR=2. 4 (95% CI=1.1-5.3; P=0.027). Breast cancer-specific survival (BCSS) was significantly worse among the BRCA2-associated cases: RR=2.0 (95% CI=1.2-3.4; P=0.010). When stage was corrected for in a multivariate analysis,... (More)
54 female breast cancer patients from 22 families with BRCA2 germ line mutations from Sweden and Denmark were compared with 214 age- and date of diagnosis-matched controls identified among breast cancer patients from South Sweden. At diagnosis, BRCA2-associated cases were more often node-positive (N+). OR=1.9 (95% confidence interval (CI)=1.0-3.6; P=0.036), and were more often clinical stage IV: OR=4.6 (95% CI=1.3-17; P=0.021) than the controls. Bilateral disease was also more common among the BRCA2-associated cases: OR=2. 4 (95% CI=1.1-5.3; P=0.027). Breast cancer-specific survival (BCSS) was significantly worse among the BRCA2-associated cases: RR=2.0 (95% CI=1.2-3.4; P=0.010). When stage was corrected for in a multivariate analysis, BCSS was no longer significantly worse for the BRCA2-associated cases: RR=1.6 (95% CI=0.85-3.1). The corresponding effect after correction for bilateral disease was: RR=1.8 (95% CI=1.0-3.1; P=0.034). The unfavourable prognosis in BRCA2-associated breast cancer seems, to a great extent, to be a consequence of the higher clinical stage at diagnosis. The increased presence of bilateral cancers appears to have less impact on survival in this group of hereditary breast cancer. Data presented here needs to be taken into account when counselling healthy carriers of BRCA2 germ line mutations. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Prognosis, Stage, Hereditary, BRCA2, Breast cancer
in
European Journal of Cancer
volume
36
issue
11
pages
1365 - 1373
publisher
Elsevier
external identifiers
  • pmid:10899649
  • scopus:0033921002
ISSN
1879-0852
DOI
10.1016/S0959-8049(00)00098-8
language
English
LU publication?
yes
id
a113843d-c27e-4363-86e1-18c59f40130e (old id 1116983)
date added to LUP
2008-07-02 14:32:47
date last changed
2017-02-12 03:23:25
@article{a113843d-c27e-4363-86e1-18c59f40130e,
  abstract     = {54 female breast cancer patients from 22 families with BRCA2 germ line mutations from Sweden and Denmark were compared with 214 age- and date of diagnosis-matched controls identified among breast cancer patients from South Sweden. At diagnosis, BRCA2-associated cases were more often node-positive (N+). OR=1.9 (95% confidence interval (CI)=1.0-3.6; P=0.036), and were more often clinical stage IV: OR=4.6 (95% CI=1.3-17; P=0.021) than the controls. Bilateral disease was also more common among the BRCA2-associated cases: OR=2. 4 (95% CI=1.1-5.3; P=0.027). Breast cancer-specific survival (BCSS) was significantly worse among the BRCA2-associated cases: RR=2.0 (95% CI=1.2-3.4; P=0.010). When stage was corrected for in a multivariate analysis, BCSS was no longer significantly worse for the BRCA2-associated cases: RR=1.6 (95% CI=0.85-3.1). The corresponding effect after correction for bilateral disease was: RR=1.8 (95% CI=1.0-3.1; P=0.034). The unfavourable prognosis in BRCA2-associated breast cancer seems, to a great extent, to be a consequence of the higher clinical stage at diagnosis. The increased presence of bilateral cancers appears to have less impact on survival in this group of hereditary breast cancer. Data presented here needs to be taken into account when counselling healthy carriers of BRCA2 germ line mutations.},
  author       = {Loman, Niklas and Johannsson, O and Bendahl, Pär-Ola and Dahl, N and Einbeigi, Z and Gerdes, A and Borg, Åke and Olsson, Håkan},
  issn         = {1879-0852},
  keyword      = {Prognosis,Stage,Hereditary,BRCA2,Breast cancer},
  language     = {eng},
  number       = {11},
  pages        = {1365--1373},
  publisher    = {Elsevier},
  series       = {European Journal of Cancer},
  title        = {Prognosis and clinical presentation of BRCA2-associated breast cancer},
  url          = {http://dx.doi.org/10.1016/S0959-8049(00)00098-8},
  volume       = {36},
  year         = {2000},
}